Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy

Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy

Show other versions (1)

Prospective randomised trials have demonstrated convincingly the benefits of drug treatment of hypertension. Treatment with conventional antihypertensive agents reduces the incidence of cardiovascular events by about that which would be expected from epidemiological data for the achieved difference...

Full description

Bibliographic Details
Main Author: Gordon T McInnes
Format: Article
Language:English
Published: Hindawi - SAGE Publishing 2000-06-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:http://jra.sagepub.com/content/1/2_suppl/S17.full.pdf
id doaj-a7baa58a1f354996978a496eec79e2d8
record_format Article
spelling doaj-a7baa58a1f354996978a496eec79e2d82021-05-02T17:25:30ZengHindawi - SAGE PublishingJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762000-06-0112_supplS17S2010.3317/jraas.2000.04810.3317_jraas.2000.048Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapyGordon T McInnes0University of Glasgow, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK, g.t.mcinnes@clinmed.gla.ac.ukProspective randomised trials have demonstrated convincingly the benefits of drug treatment of hypertension. Treatment with conventional antihypertensive agents reduces the incidence of cardiovascular events by about that which would be expected from epidemiological data for the achieved difference in blood pressure. Newer agents, such as angiotensin II receptor blockers, have potential for benefits beyond blood pressure reduction. This rationale is under evaluation in a number of long-term morbidity and mortality trials which will report over the next few years, with the largest, VALUE, due to provide results in 2004. The findings from these trials will be decisive in determining the future role of this important new class of drugs.http://jra.sagepub.com/content/1/2_suppl/S17.full.pdf
collection DOAJ
language English
format Article
sources DOAJ
author Gordon T McInnes
spellingShingle Gordon T McInnes
Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
Journal of the Renin-Angiotensin-Aldosterone System
author_facet Gordon T McInnes
author_sort Gordon T McInnes
title Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
title_short Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
title_full Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
title_fullStr Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
title_full_unstemmed Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
title_sort saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
publisher Hindawi - SAGE Publishing
series Journal of the Renin-Angiotensin-Aldosterone System
issn 1470-3203
1752-8976
publishDate 2000-06-01
description Prospective randomised trials have demonstrated convincingly the benefits of drug treatment of hypertension. Treatment with conventional antihypertensive agents reduces the incidence of cardiovascular events by about that which would be expected from epidemiological data for the achieved difference in blood pressure. Newer agents, such as angiotensin II receptor blockers, have potential for benefits beyond blood pressure reduction. This rationale is under evaluation in a number of long-term morbidity and mortality trials which will report over the next few years, with the largest, VALUE, due to provide results in 2004. The findings from these trials will be decisive in determining the future role of this important new class of drugs.
url http://jra.sagepub.com/content/1/2_suppl/S17.full.pdf
work_keys_str_mv AT gordontmcinnes savingliveslongtermmorbidityandmortalitytrialswithselectiveangiotensinreceptorblockertherapy
_version_ 1721489503927926784

Similar Items